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INTRODUCTION 
Vitamins are organic compounds that 
the host organism cannot synthesize in 
sufficient quantities and that therefore need 
to be supplied exogenously by the diet or 
commensal bacteria. Some vitamins (e.g. 
vitamin B family and vitamin C) are  
water-soluble, whereas others (e.g., vitamins 
A, D, E, and K) are hydrophobic. Both 
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ABSTRACT 
Background and aims: Vitamins are essential constituents of our diet that Longley have 
been known to influence the immune system. Vitamin D3 and B9 have received particular 
attention in recent years as these vitamins have been shown to have an unexpected and 
crucial effect on the immune response. 1, 25(OH)2D3 metabolizing enzymes and vitamin 
D receptor (VDR) are present in many cell types including various immune cells such as 
antigen-presenting-cells, T cells, B cells. 
Methods: In this mini review, we study 30 novel articles since 2009 to 2015 about the 
essential roles of vitamins in modulating a broad range of immune processes, such as 
lymphocyte activation, T-helper-cell differentiation and regulation of the immune 
response. 
Results: 1, 25(OH)2D3 has direct effect on CD
4+
 T (T-helper) cells for suppressing 
various cytokines such as IFN-γ, IL-17, IL-21 and IL-22, while enhancing the regulatory 
Tcells. In vitro studies show that Treg cells could be differentiated from naive T cells in 
vitamin B9-reduced condition. 
Conclusions: These findings provide a new link between diet and the immune system, 
which could maintain the immunological homeostasis and clarify the beneficial roles of 
vitamins in informing the design of vitamin analogs as pharmacologic agents for the 
generation and maintenance of a healthy immune condition. 
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hydrophilic and hydrophobic vitamins and 
their metabolites have diverse functions in 
many biologic events, including 
immunologic regulation responses is better. 
than regulation. Indeed, vitamin deficiency 
results in high susceptibility to infection and 
immune diseases.
1
 Until the mid-1930s, 
when the first commercial yeast-extract 
vitamin B complex and semi-synthetic 
vitamin C supplement tablets were sold, 
vitamins were obtained solely through food 
intake, and changes in diet (which, for 
example, could occur during a particular 
growing season) usually greatly altered the 
types and amounts of vitamins ingested. 
However, vitamins have been produced as 
commodity chemicals and made widely 
available as inexpensive semisynthetic and 
synthetic-source multivitamin dietary and 
food supplements and additives, since the 
middle of the 20th century. Thirteen 
vitamins are universally recognized at 
present. Vitamins are classified by their 
biological and chemical activity, not their 
structure. The largest number of vitamins, 
the B complex vitamins, function as 
precursors for enzyme cofactors, that help 
enzymes in their work as catalysts in 
metabolism.
2
 In this role, vitamins may be 
tightly bound to enzymes as part of 
prosthetic groups: For example, biotin is 
part of enzymes involved in making fatty 
acids. They may also be less tightly bound 
to enzyme catalysts as coenzymes, 
detachable molecules that function to carry 
chemical groups or electrons between 
molecules. For example, folic acid may 
carry methyl, formyl, and methylene groups 
in the cell. Although these roles in assisting 
enzyme-substrate reactions are vitamins' 
best-known function, the other vitamin 
functions are equally important. Previously 
vitamins were thought to regulate the 
immune system in an indiscriminant 
manner, but accumulating evidence has 
revealed specific functions of individual 
vitamins and their metabolites in immune 
responses.
3 
Vitamin D is a group of fat soluble 
vitamins responsible for absorption of 
calcium and phosphate in the small intestine 
and stimulates osteoclast differentiation.
4
 
Two major forms of vitamin D exist. 
Vitamin D2 (ergocalciferol), found in plants, 
is produced by ultraviolet B irradiation of 
ergosterol and can be consumed as a 
supplement or in fortified foods.
5
 Vitamin 
D3 (cholecalciferol) is synthesized in the 
human epidermis or consumed in the form 
of natural (for example, fish) or fortified 
food sources or as a supplement.
4
 Despite its 
name, vitamin D is not really a vitamin,  
it is the precursor to the potent steroid  
hormone calcitriol (also known as  
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 
which mediates numerous actions in many 
tissues of the body.
6
 Cutaneous vitamin D3 
generated by high energy UVB photons 
provides 90% of the human vitamin 
requirement. The biological half-life of  
25-OHD3 is 2 months, so this metabolite 
effectively integrates sunlight’s energy 
signal over time.
7
 With the finding of the 
vitamin D receptor (VDR) in nearly every 
tissue and the more recent discovery of 
thousands of VDR binding sites throughout 
the genome controlling hundreds of genes, 
the interest in vitamin D and its impact on 
multiple biologic processes has accelerated 
tremendously as evidenced by the 
thousands of publications each year for the 
past several years.
5
 
In the human skin, cholecalciferol is 
synthesized from 7-dihydrocholesterol when 
exposed to UVB. The production of vitamin 
D3 (D3) in the skin is not an enzymatic 
process. Vitamin D3 (cholecalciferol) is 
produced through a two-step process in 
which the B ring is broken by UV light 
(spectrum 280-320 UVB) radiation from the 
sun, forming pre-D3 that isomerizes to D3 in 
a thermosensitive but noncatalytic process.
8
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Cholecalciferol is biologically inactive and 
immediately binds to vitamin D binding 
proteins or albumin.
9
 It then enters the 
circulation and is hydroxylated in the liver, 
catalyzed by the enzymes CYP2R1 and 
CYP27A1, which results in the production 
of the inactive form 25 hydroxy vitamin D 
(25 (OH)D) which represents the main 
circulating vitamin D metabolite and is the 
most reliable parameter to define human 
vitamin D status.
10
 In the kidney, 25 (OH)D 
is further converted to the circulating 
biologically active compound calcitriol  
(1, 25(OH)2D) by the enzyme 1-α-
hydroxylase (CYP27B1) which is under 
strict control of parathyroid hormone and the 
phosphaturic hormone fibroblast growth 
factor 23 (FGF-23).
11
 Calcitriol levels are 
tightly regulated in a renal negative 
feedback loop, including inhibition of 
CYP27B1 by high levels of calcitriol and 
FGF-23 and stimulation of the enzyme 
CYP24A1 (24-hydroxylase) which 
metabolizes calcitriol into the inactive, water 
soluble form, calcitroic acid, which is then 
excreted in the bile.
12
 Circulating levels of 
calcitriol are mainly determined by renal 
CYP27B1 activity.
13
 However, other cell 
types including immune cells, also express 
CYP27B1 and are able to convert the 
inactive, circulating form 25(OH)D into the 
active hormone in an autocrine or paracrine 
manner. Especially in immune cells, such as 
macrophages and dendritic cells, a lack of 
feedback mechanisms compared to kidney 
cells allows the production of high local 
concentrations of calcitriol needed for 
immune modulation.
14
 
Vitamin D receptor (VDR) is a 
transcription factor and member of the 
steroid hormone and nuclear hormone 
receptor family. The VDR was identified in 
1969 and its crystal structure was cloned in 
1987 and binding to its natural ligand were 
characterized in 2000.
15
 Since its discovery, 
researchers have detected the VDR in many 
tissues of the body, including bone, 
pancreatic β cells, parathyroid gland, brain, 
skin, prostate, testes, heart, skeletal muscle 
tissue, breast, liver, lung, intestine, kidneys, 
adipose cells and immune response cells, 
such as macrophages, dendritic cells and 
activated B- and T-cells.
16
 It is comprised of 
3 domains: the N-terminal DNA binding 
domain with two zinc fingers that bind to the 
grooves of the DNA at discrete sites 
(VDREs), the C-terminal ligand binding 
domain, and the hinge region binding of 
these two domains together. The ligand 
binding domain structure has been solved by 
x-ray crystallography.
17
 It is comprised of 
12 helices. The terminal helix serves as a 
gating mechanism closing around the 
incorporated ligand and forming an interface 
for coactivators as well as facilitating the 
interaction of VDR with its heterodimer 
partner, generally RXR. Although VDR 
preferentially binds to RXR, creating a 
VDR-RXR dimer, VDR can also bind other 
receptors of the nuclear receptor 
superfamily, which include thyroid, vitamin 
A, PPAR-γ and other orphan receptors.18 
The VDR-RXR dimer can regulate genes in 
several systems and tissues. Although there 
is substantial variability in quence of 
VDREs, the most prevalent motif for the 
VDRE sequence consists of two half-sites, 
each with the six-nucleotide consensus 
sequence, GGTCCA, separated by 3 other 
nucleotides of any sequence. This motif is 
known as Direct Repeat 3 (DR3), although 
other configurations of VDRE-binding sites, 
including DR6 and DR4, exist in some 
vitamin D-regulated genes.
19
 VDR binding 
to its VDRE then recruits coregulatory 
complexes required for its genomic activity. 
These complexes can be both gene and cell 
specific, enabling the selectivity of 
1,25(OH)2D action from cell type to cell 
type. These complexes include a subunit that 
directly binds to the VDR generally through 
an LXXLL motif along with a number of 
Mansouri R, et al. The vitamin D3 and vitamin B9 in immune system 
72 
subunits that contain enzyme activity such 
as histoneacetyl transferases (coactivators 
such as the SRC family) ordeacetylases 
(corepressors such as SMRT and NCoR), 
methyl transferases and demethylases, 
ATPase-containing nucleosomal-remodeling 
activity (SWI/SNF), and links to RNA 
polymerase II.
5
 
In common with natural killer cells 
(NK) and cytotoxic T-lymphocytes 
(cytotoxic T-cells), macrophages and their 
monocyte precursors play a central role in 
initial non-specific immune responses to 
pathogenic organisms or tissue damage-so 
called cell-mediated immunity. Consistent 
with the earlier seminal observations of 
extra renal 1α-hydroxylase activity in 
patients with sarcoidosis, the effects of 
vitamin D on macrophage function have 
been central to many of the new 
observations implicating vitamin D in the 
regulation of immune responses. Their role 
is to phagocytose pathogens or cell debris 
and then eliminate or assimilate the resulting 
waste material. In addition, macrophages 
can interface with the adaptive immune 
system by utilizing phagocytic material for 
antigen presentation to T-lymphocytes  
(T-cells). 
For many years, the key action of 
vitamin D on macrophages was thought to 
be its ability to stimulate differentiation of 
precursor monocytes to more mature 
phagocytic macrophages.
20,21
 This concept 
was supported by observations showing 
differential expression of VDR and  
1α-hydroxylase during the differentiation of 
human monocytes macrophages.
22
 The latter 
report also emphasized early studies 
showing that normal human macrophages 
were able to synthesize 1,25(OH)2D3 when 
stimulated with interferon gamma (IFN-γ). 
Localized activation of vitamin D, coupled 
with expression of endogenous VDR was 
strongly suggestive of an autocrine or 
intracrine system for vitamin D action in 
normal monocytes/macrophages. However, 
confirmation of such a mechanism was only 
obtained in 2006 when Robert Modlin and 
colleagues carried out DNA array analyses 
to define innate immunity genes that were 
specifically modulated in monocytes by 
Mycobacterium tuberculosis (M. tb). In a 
seminal investigation both the VDR and the 
gene for 1α-hydroxylase (CYP27B1) were 
shown to be induced following activation of 
the principal pathogen recognition receptor 
for M. tb, toll-like receptor 2/1 (TLR2/1.
23
 
Subsequent experiments confirmed that 
precursor 25OHD3 was able to induce 
intracrine VDR responses in monocytes that 
had been treated with a TLR2/1 activator. In 
particular, the TLR2/1–25OHD3 
combination stimulated expression of the 
antibacterial protein cathelicidin, so that 
vitamin D was able to promote monocyte 
killing of M. tb. Notably, the ability to 
promote expression of the antibacterial 
protein following a TLR2/1 challenge was 
directly influenced by the 25OHD3 status of 
the donor serum used for monocyte culture. 
More recently, scientists have shown that 
vitamin D supplementation in vivo can also 
enhance TLR2/1-induced cathelicidin 
expression. Cathelicidin was identified 
several years ago as a target for 
transcriptional regulation by 1,25(OH)2D3-
liganded VDR, in that its gene promoter 
contains a functional vitamin D response 
element (VDRE).
24
 Interestingly, this VDRE 
occurs within a small interchangeable 
nuclear element (SINE) sequence which 
only appears to be present in the cathelicidin 
gene promoter of higher primates, 
suggesting that vitamin D regulation of this 
facet of innate immunity is a relatively 
recent evolutionary development.
25
 
Recent reports have not only underlined 
the importance of cathelicidin as a target for 
vitamin D but also suggest that this 
mechanism may be more complex than 
initially thought. As yet, the precise signal 
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system by which TLR activation induces 
expression of VDR and 1α-hydroxylase 
remains unclear. Promoter-reporter analysis 
of the events involved in transcriptional 
regulation of CYP27B1 suggests that TLR4-
mediated induction of the enzyme involves 
JAK-STAT, MAP kinase and nuclear factor 
kapa β (NF-κβ) pathways, and that these 
synergize with IFN-γ mediated induction of 
CYP27B1.
26
 However, other studies have 
proposed that TLR2/1 induction of  
1α-hydroxylase occurs indirectly as a 
consequence of TLR2/1 induced interleukin-15 
(IL-15) which is a potent inducer of 
CYP27B1 and 1α-hydroxylase activity.27 In 
a similar fashion, interleukin 17A (IL-17A) 
has been shown to enhance 1,25(OH)2D3 
mediated induction of cathelicidin, although 
this response does not appear to involve 
transcriptional regulation of 1α-hydroxylase 
or increased VDR sensitivity.
28 
Regulation of the antibacterial protein 
by 1,25(OH)2D3 has been described for a 
wide variety of cell types other than 
macrophages, including keratinocytes, lung, 
epithelial cells, myeloid cell lines, and 
placental trophoblasts.
29,30
 In some cases, 
this appears to involve an intracrine 
response similar to that reported for 
monocytes. However, the mechanisms 
controlling local synthesis of 1,25(OH)2D3 
in these cells vary considerably. In 
keratinocytes, low baseline expression of 
1α-hydroxylase is enhanced following 
epidermal wounding by transforming growth 
factor beta (TGFβ).31 The resulting rise in 
1,25(OH)2D3 concentrations upregulates 
expression of TLR2 and TLR4 by 
keratinocytes, thereby priming these cells 
for further innate immune responses to 
pathogens or tissue damage. By contrast, in 
trophoblasts, induction of cathelicidin and 
subsequent bacterial killing by 25OHD3 
appears to be due to constitutive  
1α-hydroxylase activity, which is not further 
enhanced by TLR activation. The latter may 
be due to the rapid non-immune induction of 
1α-hydroxylase and VDR which occurs 
within the placenta during early gestation.
32
 
Dendritic cells (DCs) are antigen 
presenting cells (APCs) are important in 
initiating CD
4+
 T cells responses. Expression 
of VDR by purified tissue DCs was first 
reported in 1987. Subsequent studies using 
populations of DCs isolated from skin 
(Langerhans cells) provided evidence that 
1,25(OH)2D3 could act to attenuate antigen 
presentation.
33
 In functional studies, 
1,25(OH)2D3 treatment of human DCs in 
vitro results in reduced expression of the 
cost imulatory molecules CD80 and CD86 
and decreased expression of HLA-DR and 
the maturation marker CD83, all associated 
with an immature DC phenotype.
34
 
Vitamin D inhibits differentiation and 
maturation of human DCs invitro by 
suppressing the IL-12 production from DCs 
and increasing IL-10 production.
35
 This is an 
important immunosuppressive activity as  
IL-12 is an important cytokine in inducing 
Th1 development.
34
 1,25(OH)2D3 inhibits 
the differentiation, maturation, and immune 
stimulatory capacity of DCs. Canning et al. 
confirm that 1,25(OH)2D3 suppresses 
monocyte differentiation into DCs, thereby 
generating immature DCs. This suppresses 
DC ability to stimulate T-cell proliferation.
36
 
Most of the direct immune modulatory 
properties of 1,25(OH)2D3 on DCs are 
proposed to occur in myeloid (mDCs) and 
not plasmacytoid DCs (pDCs). A study by 
Penna and et al. suggest that although both 
primary human blood-derived mDCs and 
pDCs express comparable levels of VDR 
and upregulate the primary response gene 
CYP24 upon culture with 1,25(OH)2D3, 
only the tolerogenic properties of mDCs are 
modulated upon culture with 1,25(OH)2D3.
37
 
1,25(OH)2D3 negatively regulates the 
differentiation, maturation, and immune 
stimulatory capacity of DCs by decreasing 
the expression of MHC class II, CD40, 
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CD80, and CD86.
38
 In addition, 
1,25(OH)2D3 decreases the synthesis of  
IL-6, IL-12, and IL-23.
39
 
The other major type of adaptive 
immune cells, T cells, is also thought to be 
an important target for the immune 
modulatory effects of different forms of 
vitamin D. The development of lymphocytes 
takes place in the thymus with VDR being 
expressed in medullary thymocytes but not 
in the less mature cortical thymocytes. 
However, once cells leave the thymus and 
enter the circulation as T or B cells VDR 
expression is lost until these cells are 
activated to proliferate by mitogens Indeed, 
1,25D is a potent inhibitor of T-cell 
proliferation, blocking the transition from 
early G1 phase to late G1 phase, but having 
no effect on transition from Go (resting) to 
early G1 or from late G1 to S phase. Weak 
TCR signaling via the mitogen-activated 
protein kinase p38 pathway induced VDR 
expression. The T cells subsequently  
up-regulated phospholipase C-gamma1 
(PLC-γ1) expression 75-fold , enabling them 
to flux calcium and become fully activated. 
PLC-γ1 induction appeared to be  
VDR-dependent. The dependence of T cell 
activation on VDR expression has not been 
demonstrated in vivo.
40
 
VDR expression by these cells is very 
low in resting conditions but upon activation 
and proliferation, T and B cells up-regulate 
VDR expression significantly, allowing 
regulation of up to 500 vitamin D responsive 
genes which influence differentiation and 
proliferation of these cells.
41
 Since 1983 it 
has been described that 1,25(OH)2D 
inhibited T cell proliferation and the 
secretion of select cytokines after mitogen 
stimulation four potential mechanisms by 
which vitamin D may influence T cell 
function have been proposed: 1) direct, 
endocrine effects on T cells mediated via 
systemic calcitriol. 2) Direct, intracranial 
conversion of 25(OH)D to calcitriol by  
T cells. 3) Direct, paracrine effects of 
calcitriol on T cells following conversion of 
25(OH)D to calcitriol by monocytes or 
dendritic cells. 4) Indirect effects on antigen 
presentation to T cells mediated via 
localized APC affected by calcitriol. 
In principle, vitamin D exposure leads 
to a shift from a pro inflammatory to a more 
tolerogenic immune status, including very 
diverse effects on T cell subtypes: Calcitriol 
suppresses T helper (Th) cell proliferation, 
differentiation and modulates their cytokine 
production.
42
 In particular, treatment of  
T cells with calcitriol or analogs inhibits the 
secretion of pro inflammatory Th1 [IL2, 
interferon-γ (IFN- γ), tumor necrosis factor 
α (TNF- α)], Th9 (IL9) and Th22 (IL22) 
cytokines,
43
 but promotes the production of 
more anti-inflammatory Th2 cytokines (IL3, 
IL4, IL5, IL10).
44,45
 The decrease in the 
production of IL-2 and IFNγ by 
1,25(OH)2VD3 is partially mediated by 
binding of the VDR–RXR complex to the 
VDRE in the promoters of genes encoding 
IL-2. IL17 producing Th17 cells are also 
affected by vitamin D. Inhibition of Th17 
activity seems to play a major role in the 
treatment of autoimmune diseases as shown 
in non-obese diabetic (NOD) mice.
46
 
Recently, calcitriol was found to directly 
suppress IL17 production on a 
transcriptional level,
47
 and activated human 
T-cells exposed to calcitriol produced 
significantly decreased levels of IL17, 
interferon-γ and IL21.48 The same study also 
revealed a change toward a tolerogenic 
phenotype, including increased expression 
of genes typicaland regulatory markers 
FOXP3, CTLA-4, and IL-10 for regulatory 
T cells (Tregs), by adding a combination of 
calcitriol and IL2 to human primary T cell 
cultures. In addition, 1,25(OH)2D 
upregulated the gut homing receptor CCR9 
and inhibited CXCR3 on T cells potentially 
changing the homing properties of the Th 
cells.
49
 Vitamin D and 1,25(OH)2D inhibited 
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Th1 and Th17 responses, induced T reg 
responses, and controlled proliferation and 
Th cell localization.
39
 
INKT cells are also vitamin D targets 
.Development and function of iNKT cells 
depends on expression of the VDR and 
vitamin D.
50,51
 In vitro, 1,25(OH)2D 
inhibited iNKT cell derived IL-17 and 
induced IL-4 and IL-5. The requirement for 
the VDR in the development of iNKT cells 
was traced to regulation of the survival of 
maturing iNKT cells in the thymus. Vitamin 
D also controls iNKT cell expansion during 
development.
51
 
Vitamin D has also been proposed as a 
regulator of Th2 mediated disease such as 
allergy and asthma. In vitro, 1,25(OH)2D 
treatment of T cells has been shown to 
increase IL-4 secretion by human and mouse 
Th cells.
41,52
 IL-13 has been shown to be 
induced or decreased by 1,25(OH)2D 
treatment of human T cells.
53
 25-
hydroxyvitamin D3 (25(OH)D3) is the 
inactive precursor of 1,25(OH)2D3 and is 
considered the best parameter for evaluation 
of the vitamin D status of a subject. The 
normal range of serum 25(OH)D3 
concentrations is 25–170 Nm.54 The serum 
concentration of the active 1,25(OH)2D3 is 
approximately 1000-fold lower (60–110 
pM) and far below the effective 
concentration of 1,25 (OH)2D3 found in in 
vitro studies. Thus, in most in vitro studies 
more than a 100-fold higher concentration of 
1,25 (OH)2D3 than found in serum is often 
required to obtain an effect.
55
 It has 
therefore been suggested that the level of 
circulating 1,25(OH)2D3 is too low to affect 
immune responses in vivo, and that 
sufficient levels are obtained by local 
conversion of 25(OH)D3 to 1,25 (OH)2D3.
10
 
In accordance, it has been shown that 
activated antigen presenting cells (APC) 
express the 25(OH) D-1α hydroxylase 
CYP27B1 that converts 25(OH)D3 to 
1,25(OH)2D3, and that APC can produce 
1,25(OH)2D3 from 25(OH)D3 in vitro and 
respond to this through the vitamin D 
receptor (VDR) in an autocrine fashion.
23
 
Elevated levels of 1,25(OH)2D3 in 
association with hypercalcemia have been 
observed in patients with sarcoidosis, 
tuberculosis, and other infections and 
inflammatory diseases in which the 
pathology is characterized by granuloma 
formation, supporting the hypothesis that 
activated macrophages can produce 
significant amounts of 1,25(OH)2D3 in 
vivo.
56
 Like APC, activated T cells express 
the VDR and CYP27B1.
7
 However, whether 
T cells can convert 25(OH)D3 to 
1,25(OH)2D3 in physiological relevant 
concentrations and respond to this in an 
autocrine fashion is a matter of debate. Most 
studies on the effect of vitamin D on  
T cells have not addressed this question as 
they investigated the direct effects of  
supra-physiological concentrations of 
1,25(OH)2D3 and not how 25(OH)D3 affects 
T cell responses. One study has shown that 
isolated T cells have the ability to convert 
25(OH)D3 to 1,25(OH) 2D3 in 
concentrations that actually affect vitamin D 
responsive genes in an autocrine fashion.
40
 
In agreement, scientists found that purified 
CD
4+
 T cells have the ability to produce 
substantial amounts of 1,25(OH)2D3 when 
activated in the presence of 25(OH)D3.
57
 In 
contrast, another recent study found that 
although activated T cells do express 
CYP27B1, the expression level is not 
sufficiently high to allow production of 
1,25(OH)2D3 in concentrations that affect 
vitamin D responsive genes. The authors 
found that 25(OH)D3 only affected T cell 
responses when APC were present, and 
suggested that APC locally secrete sufficient 
amounts of 1,25(OH)2D3 to directly 
influence the surrounding T cells in a 
paracrine fashion. Other important players 
influencing the bioavailable levels of 
vitamin D are the vitamin D-binding protein 
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(DBP) and albumin. 25(OH)D3 and 
1,25(OH)2D3 circulate bound to DBP  
(85–90%) and albumin (10–15%) with less 
than 1% in their free form.
58
 Studies of DBP 
knock-out mice have shown that DBP acts 
as a vitamin D reservoir by protecting 
25(OH)D3 and 1,25 (OH)2D3 from 
degradation and renal secretion.
15
 However, 
DBP also sequesters 25(OH)D3 and 
1,25(OH) 2D3 and inhibits their action on 
monocytes, DC and keratinocytes in vitro.
15
 
How DBP affects T cell responses to 
25(OH)D3 still needs to be determined. The 
objectives of this study were to further 
elucidate whether T cells have the ability to 
convert 25(OH)D3 to 1,25(OH)2D3 in 
proportions that affect a panel of vitamin D 
responsive genes in an autocrine fashion and 
to investigate how DBP regulates T cell 
responses to 25(OH)D3. 
Like T-cells, active but not inactive  
B-cells express the VDR. Consequently, 
initial studies indicated that 1,25(OH)2D3 
could directly regulate B-cell proliferation 
and immunoglobulin (Ig) production.
59
 In  
B-cells, anti-proliferative effects of calcitriol 
such as inhibition of differentiation, 
proliferation, initiation of apoptosis and 
decreased immunoglobulin production were 
initially considered to be exclusively 
indirectly mediated by T helper (Th) cells.
60
 
expression of CYP27b1 was also detected in 
B-cells, indicating that B cells may be 
capable of autocrine/intracranial responses 
to vitamin D. More recent studies confirmed 
additional direct effects of calcitriol on B 
cell homoeostasis, including inhibition of 
memory- and plasma-cell generation, as well 
as promotion of apoptosis of 
immunoglobulin-producing B cells.
61
 This 
control on B cell activation and proliferation 
may be clinically important in autoimmune 
diseases as B-cells producing auto reactive 
antibodies play a major role in the 
pathophysiology of autoimmunity.
12
 
Autoimmune diseases are characterized 
by a loss of immune homeostasis resulting 
in corrupted self-antigen recognition 
followed by the destruction of body tissue 
by auto reactive immune cells. A 
combination of genetic predisposition, 
epidemiological risk factors,
62
 and 
environmental contributors contributes to 
the development of autoimmune diseases. 
One important factor may be the availability 
of sufficient vitamin D levels as various 
epidemiological studies suggest associations 
between vitamin D deficiency and a higher 
incidence of autoimmune diseases, such as 
T1D, MS, systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA) and 
inflammatory bowel disease (IBD).
63
 
In animal models for T1D, MS, SLE, 
IBD and autoimmune uveitis, administration 
of calcitriol either prevented or ameliorated 
autoimmunity. Studies with vitamin D 
deficient or VDR knock-out animals show 
increased inflammation and susceptibility to 
T1D and Crohn’s disease, disturbed T cell 
homing and lack of host protection from 
bacterial invasion and infection.
64
 
Serum 25(OH)D is considered the most 
accurate marker for vitamin D status.
65
 
While the Endocrine Society advocates that 
levels below 20 ng/mL (50 nmol/L) should 
define deficiency, levels ranging from 20 to 
29.9 ng/mL (52–72 nmol/L) should define 
insufficiency and levels above 30 ng/mL  
(75 nmol/L) should define sufficiency, the 
Institute of Medicine (IOM) considers levels 
of >20 ng/mL to be sufficient for the 
majority of the general population.
49
 This 
latter classification is based largely on 
vitamin D’s effects on bone and mineral 
homeostasis. The optimal 25(OH)D serum 
level regarding other aspects of human 
health is still under debate.
66
 For immune-
mediated diseases, experts suggest that even 
higher serum 25(OH)D levels may be 
needed to lead to positive effects.
67
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Calcitriol is well known for its diverse 
pharmacological activities, including 
modulation of cell growth, neuromuscular 
and immune function and reduction of 
inflammation. Calcitriol and its analogs 
exert potent effects on cellular 
differentiation and proliferation regulate 
apoptosis and produce immune modulatory 
effects.
68 
Vitamin D has several important roles 
in the skin. Many in vitro and in vivo studies 
demonstrate dose-dependent effects of 
vitamin D on cell proliferation and 
differentiation.
11,69
 Although the mechanisms 
that mediate the anti-proliferative and  
pro-differentiating effects of vitamin D 
analogs on keratinocytes are not completely 
understood, it is well known that these 
effects are at least in part genomic and 
mediated by VDRs (1,25-dihydroxyvitamin 
D3).
11
 Vitamin D can reduce the risk of skin 
infection through modulating the production 
of various antimicrobial peptides and the 
cytokine response.
70
 It is possible that 
vitamin D could enhance T helper type 2 
responses. Vitamin D deficiency is related to 
a high number of skin disorders, including 
skin cancer, autoimmune skin disorders, 
photo dermatoses, atopic dermatitis and 
psoriasis. Vitamin D and its analogs have 
already been successfully used in the 
therapy of atopic dermatitis, psoriasis, 
vitiligo, acne and rosacea.
71
 Most of the 
studies are devoted to treatment of psoriasis. 
The highly variable nature of psoriasis and 
its individual presentations in patients can 
make choosing the most appropriate 
treatment difficult. Currently available 
synthetic vitamin D analogs that have been 
found to be safe and effective in topical 
treatment of psoriasis include calcipotriol 
(or calcipotriene), max-acalcitol, tacalcitol 
and hexafluoro-1a, 25-dihydroxyvitamin 
D3.
72
 According to the literature, the rate of 
treatment success with vitamin D and its 
analogs varies from 4% to 53%,
73
 and many 
of them have significant adverse effects. 
Calcipotriol is considered as a highly 
effective topical agent for the treatment of 
hyper proliferative skin diseases, such as 
psoriasis.
74
 Calcipotriol exerts only 
negligible systemic effects on calcium 
homeostasis. Thus, eliminating the risk of 
the main significant side effects of 
hypercalciuria, hypercalcemia and bone 
calcium mobilize.
75
 
The role of vitamin D and its analogs in 
cancer treatment and prevention was 
investigated in different research tracks 
including clinical and epidemiological 
studies. According to extensive 
epidemiological research reports,
64
 it was 
found that there is a clear association 
between various factors responsible for 
vitamin D levels in the body (e.g. geography 
and latitude, history of sun exposure, 
lifestyle) and increased morbidity from 
cancer. It was also found that vitamin D and 
its analogs inhibit proliferation of cancer 
cells derived from multiple tissues.
76
 Further 
studies are required to clarify the molecular 
mechanisms of the anticancer activity of 
vitamin D and its various analogs. From the 
current literature on the subject, it appears 
that the compound is not suitable for use in 
cancer as a single or primary anticancer 
agent but as an adjuvant in combination 
chemotherapy, where it can aid the actions 
of other cytotoxic agents, particularly those 
of the alkylating agents (which are not cell 
cycle specific). The anticancer vitamin D 
analogs include new calcipotriol-derived 
compounds, diastereomeric and geometric 
analogs of calcipotriol, seocalcitiol,  
20-hydroxyvitamin D2 analog, 5-butyloxazole 
unit analog and additional analogs containing 
a structurally modified side chain.
77-79
 The 
dominant side effects of vitamin D, 
hypercalcemia and hypercalciuria, resulted 
in limiting the use of vitamin D in cancer 
treatment.
80
 To overcome this problem, 
more than 3000 vitamin D analogs have 
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been synthesized in recent years.
81
 Some of 
these analogs have been found to be more 
effective and less toxic than vitamin D, 
justifying their development and 
introduction to the market.
82
 BGP-13 and 
BGP-15, calcipotriol derived vitamin D3 
analogs, are good examples of more-
effective and less-toxic analogs than vitamin 
D.
76
 BGP-15 is a calcipotriol-based analog 
where the 24-OH has been substituted by a 
chloride atom on the side chain of the 
calcipotriol molecule. BGP-13 and BGP-15 
have been shown to induce apoptosis and 
inhibit prostate and breast cancer growth in 
vitro and in mice in vivo.
77
 Antitumor 
effects of vitamin D and its analogs were 
also demonstrated in humans, when they 
were used either alone or in combination 
with other chemotherapy drugs Vitamin D 
activity is expressed also by causing tumor 
regression and inhibition of tumor growth, 
in addition to counteracting their mutagenic 
effect by inducing apoptotic cell death. 
Some evidence suggests that this vitamin 
could be used in high doses as a 
prophylactic agent for prevention of 
colorectal, prostate and breast cancer 
development. Only large-scale long-term 
research will reveal which vitamin D 
analogs, either alone or in combination with 
other drugs, could serve as effective 
therapeutic agents for cancer.
83
 
Type 1 diabetes is an autoimmune 
disease characterized by the immune-
mediated destruction of insulin-producing b 
cells from islets of Langerhans in the 
pancreas. As mentioned above, vitamin D 
plays a vital part in the normal functioning 
of the immune system and its deficiency 
could lead to impaired functioning of the 
immune system. It was shown that vitamin 
D mediates insulin secretion and glucose 
uptake,
84
 and also regulates insulin receptor 
gene expression. Epidemiological studies 
have shown a direct correlation between the 
increase in the prevalence of the disease and 
deficiency of vitamin D. The ability of a 
potent vitamin D analog: 2α-Methyl-19-nor-
(20S)-1,25-dihydroxyvitamin D3 (2AMD), 
to prevent type 1 diabetes was determined in 
an Ins2/non-obese diabetic (NOD) model. 
2AMD suppresses development of type 1 
diabetes, preserves islet cells and has a 
significant impact on B cell survival and 
function.
85
 A detailed mechanism of 
antidiabetic activity of vitamin D in type 2 
diabetes is unclear Lifestyle factors leading 
to type 2 diabetes, including obesity, aging 
and lack of physical activity. It can also 
cause vitamin D deficiency. It is only known 
that vitamin D regulates direct and indirect 
action on insulin-producing cells in the 
pancreas. Vitamin D can directly influence 
the muscle and fat cells, and can improve 
insulin action through reducing insulin 
resistance as well as reducing inflammation 
which is commonly present in patients with 
type 2 diabetes.
86
 A small-scale post hoc 
analysis of a bone study revealed that daily 
calcium (500 mg) and vitamin D (700 IU) 
supplementation for three years prevented a 
further rise in fasting blood glucose in a 
subgroup with impaired fasting blood 
glucose (100–125 mg/dl) at a baseline.87 
Multiple Sclerosis (MS) is a chronic 
and a common inflammatory disorder of the 
central nervous system (CNS) characterized 
with myelin loss, progressive neurological 
dysfunction, gliosis, and unstable degrees of 
axonal pathology that initiated by auto 
reactive T cells that recognize central 
nervous system antigens.
88
 Various genetic 
and environmental risk factors appear to 
interact and contribute to MS. In genetics, 
several human leukocyte antigen alleles 
(more particularly HLA-DRB1*1501) could 
favor the disease whereas others could be 
protective. Some of the genes involved in 
vitamin D metabolism (e.g. CYP27B1) also 
have a significant role in MS.
89
 Based on 
epidemiological studies, three environmental 
risk factors were identified: 1) previous 
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Epstein-Barr virus infection 2) vitamin D 
insufficiency 3) and cigarette smoking. 
Some clinical findings strongly suggest 
that vitamin D status influences the relapse 
rate and radiological lesions in MS 
patients. It was suggested that changes in 
vitamin D serum concentrations are 
correlated with MS.
90
 Although the results 
of adequately powered randomized clinical 
trials using vitamin D supplementation 
have not yet been reported, vitamin D is a 
promising candidate as modulator of 
disease activity in MS. 
Vitamin B is recognized as a family 
comprising eight different members. All of 
B vitamins are water-soluble, and they are 
involved in various pathways of cell 
metabolism. Vitamin B is essential for the 
synthesis, replication, and repairing of 
nucleotides for DNA and RNA and is thus 
required for cell proliferation and survival. 
Vitamin B9 deficiency also inhibits the 
activity of CD
8+
 T cells and reduces the 
proliferative responses of lymphocytes and 
natural killer cell activity; in turn ,this 
inhibition is associated with decreased 
resistance to infections. Consequently, 
vitamin B6 deficiency leads to various 
impairments of immunity, such as 
lymphoid atrophy and reduced numbers of 
lymphocytes (3); conversely, vitamin B6 
supplementation bolsters these weakened 
immune responses. Like vitamin B6, 
vitamin B9 (also known as folate and folic 
acid) is essential for nucleic acid and 
protein synthesis,
91
 and in adequate levels 
of vitamin B9 dramatically alter the 
immune response. Among the vitamins B, 
vitamin B6 is essential for metabolism of 
nucleic acids, amino acids, and lipids and 
thus influences cell growth Vitamin B9 is 
derived from both diet and commensal 
bacteria.
92
 Additionally, the vitamin B9 
receptor folate receptor 4 (FR4) is both a 
marker of Treg cells and is 
immunologically functional.
93
 
Folate receptor 4, a vitamin B9 
receptor, is highly expressed on the 
surfaces of Treg cells, implying a specific 
function of this vitamin in these cells. In 
particular, recent study revealed that 
vitamin B9 is crucial in the maintenance of 
Treg cells. In the absence of vitamin B9, 
naive Tcells can differentiate in to Treg 
cells, but differentiated Treg cells fail to 
survive owing to the decreased expression 
of anti-apoptotic molecules (Bcl-2).
93,94
 
A recent study demonstrated an 
additional function of the vitamin B family 
in the control of immune responses via 
mucosa- associated invariant T (MAIT) 
cells. MAIT cells are unconventional T cells 
that express a semi-invariant αβ T cell 
receptor that is restricted by the MHC class 
I-related molecule MR1. These cells are 
mostly found in the intestine, liver, and 
lung.
65
 Because MAIT cells can react 
rapidly to bacterial infections (e.g. 
Escherichia coli, Klebsiella pneumoniae, 
and Mycoplasma tuberculosis), it was 
supposed that the antigen presented to MR1 
was bacteria-derived molecules. However, a 
recent study clarified that, in fact, bacterially 
produced metabolites of vitamin B9 and 
vitamin B2 bound to MR1 are presented as 
antigen to MAIT cells. Furthermore, like 
vitamin B2 derivatives, the vitamin B9 
metabolite, and 6-formyl pterin. (6-FP) bind 
to MR1 but, unlike vitamin B2 derivatives, 
fails to activate MAIT cells.
96
 These findings 
suggest that, depending on their metabolism 
by commensal bacteria and presentation by 
MR1, members of the vitamin B family can 
act either as positive or negative regulatory 
ligands for MAIT cells.
97
 
 
CONCLUSION 
Clinical evidence has long indicated that 
in adequate vitamin intake disrupts host 
immunity. Thus, they predispose humans to 
infectious and inflammatory diseases. 
Accumulating evidence has revealed the 
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molecular and cellular mechanisms underlying 
myriad functions of vitamins in innate and 
acquired immune responses. Growing interest 
exists in the physiologic role of vitamin D as 
an essential mediator in maintaining a healthy 
and functional immune system. The active 
form of vitamin D 1,25(OH)2D3 influences 
innate and adaptive immunity. It acts on APCs 
and T cells to promote peripheral tolerance via 
inhibition of inflammatory responses and 
induction of Tregs. Vitamin B9 is crucial for 
the maintenance of Treg cells. Intriguingly, 
vitamin B9 was required for the survival of 
differentiated Treg cells, but was not 
necessary for the differentiation of naive T 
cells into Treg cells. As the mechanism of 
FR4-mediated Treg-cell maintenance, 
scientists considered initially that the 
proliferative activity of Treg cells could 
require large amounts of vitamin B9 as a 
source of nucleotides for DNA and RNA. 
However, the amounts of intracellular vitamin 
B9 were identical between Treg and non-Treg 
cells, implying that FR4 specifically 
recognizes extracellular vitamin B9 for the 
maintenance of Treg cell survival, consistent 
with a report that FR4 expressed on Treg cells 
contributes to their immune function and 
survival. The complex functions of vitamins in 
the regulation of the immune system efforts 
likely will enable scientists to refine our 
understanding of the mechanisms underlying 
the immunologic roles of various vitamins and 
to advance the development of vitamin-
dependent therapeutic agents for the control of 
infectious and immune diseases. These 
findings clarify the beneficial roles of vitamins 
in the maintenance of immunologic 
homeostasis and inform the design of vitamin 
analogs as pharmacologic agents for the 
generation and maintenance of a healthy 
immune condition. 
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